Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071904
Chunk: 89

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 89
---
|-------:|:--|:----|:-----|--------:|:--|
| Net cash proceeds from operating activities              |     | $                            |  6,007 |   |     | $    |   9,391 |   |
| Net cash used for investing activities                   |     |                              |   (395 | ) |     |      |    (150 | ) |
| Net cash used for financing activities                   |     |                              | (3,084 | ) |     |      | (11,196 | ) |
| Net change in cash, cash equivalents and restricted cash |     | $                            |  2,528 |   |     | $    |  (1,955 | ) |

Cash Flows from Operating Activities For the three months ended March 31, 2025, net cash proceeds from operating activities were approximately $6.0 million, attributable to the changes in operating assets and liabilities that provided $27.2 million of cash and other non-cash reconciling items of $4.9 million related to stock-based compensation, change in fair value of debt and liability instruments, financing costs, depreciation and amortization and non-cash operating lease cost and change on fair value of derivative liabilities, partially offset by our net loss of $26.1 million. For the three months ended March 31, 2024, net cash proceeds from operating activities were approximately $9.3 million, attributable to the changes in operating assets and liabilities that provided $23.1 million of cash and other non-cash reconciling items of $10.6 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cash operating lease cost, partially offset by our net loss of $24.4 million. Cash Flows from Investing Activities For the three months ended March 31, 2025, net cash used for investing activities was approximately $0.4 million and was related to the $0.2 million purchase of Gloperba Ex-U.S. rights in-process research and development assets and $0.2 million related to payments of deferred consideration for the Romeg intangible asset acquisition under the Romeg License Agreement. For the three months ended March 31, 2024, net cash used for investing activities was approximately $0.2 million, related to payments of deferred consideration for the Romeg intangible asset acquisition. Cash Flows from Financing Activities For the three months ended